...
首页> 外文期刊>Journal of Microencapsulation: Microcapsules Liposomes Nanoparticles Microcells Microspheres >Catechin-loaded Eudragit microparticles for the management of diabetes: formulation, characterization and in vivo evaluation of antidiabetic efficacy
【24h】

Catechin-loaded Eudragit microparticles for the management of diabetes: formulation, characterization and in vivo evaluation of antidiabetic efficacy

机译:加载CaeteChin的Eudragit微粒用于糖尿病的管理:制剂,表征和体内抗糖尿病疗效评估

获取原文
获取原文并翻译 | 示例
           

摘要

Catechin (CT) is natural molecule proved for antidiabetic activity. Clinical application of CT is highly restricted because of its low bioavailability and ineffectiveness in in vivo conditions. Therefore, the main objective of the present investigation was to formulate CT-loaded Eudragit RS 100 microparticles and evaluated for its potential against diabetes. CT microparticles showing highest entrapment efficiency of 92.3 +/- 6.5% and higher percentage yield of 63.46 +/- 4.3% was selected as optimised formulation. CT microparticles treated rats showed significantly lower blood glucose, cholesterol, LDL, free fatty acid and triglyceride concentrations in comparison to pristine CT-treated rats. The glucose and lipid profiles of microparticle formulation were akin to normal rats. Moreover, CT microparticles did not produce obesity even after 60 days which is a comment side effect of antidiabetic drugs. These results indicate that the CT microparticles can be applied as potential and safe carrier for the treatment of diabetes.
机译:儿茶素(CT)是一种天然的抗糖尿病活性分子。由于CT的生物利用度低且在体内条件下无效,其临床应用受到高度限制。因此,本研究的主要目的是制备载CT的Eudragit RS 100微粒,并评估其抗糖尿病的潜力。CT微粒的包封率最高,为92.3+/-6.5%,产率较高,为63.46+/-4.3%,被选为优化配方。与未经CT处理的大鼠相比,经CT微粒处理的大鼠的血糖、胆固醇、LDL、游离脂肪酸和甘油三酯浓度显著降低。微粒制剂的葡萄糖和脂质分布与正常大鼠相似。此外,CT微粒即使在60天后也不会产生肥胖,这是抗糖尿病药物的一个重要副作用。这些结果表明,CT微粒可以作为潜在的、安全的糖尿病治疗载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号